# Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to $V_H$ gene mutation status

Pawel Grabowski, Magnus Hultdin, Karin Karlsson, Gerard Tobin, Anna Åleskog, Ulf Thunberg, Anna Laurell, Christer Sundström, Richard Rosenquist, and Göran Roos

B-cell chronic lymphocytic leukemia (CLL) consists of 2 prognostic entities where cases with mutated immunoglobulin  $V_H$ genes have better outcome than unmutated cases.  $V_H$ -mutated CLLs display longer telomeres compared with unmutated cases and telomere length has been indicated to predict outcome, although the prognostic value of telomere length has not been fully established in CLL. We analyzed telomere length,  $V_H$  gene mutation status, and clinical parameters in a large series of CLL. Telomere length was assessed by quantitative polymerase chain reaction (PCR), giving a very good correlation to telomere length estimated by Southern blotting (P < .001). The prognostic information given by mutation status (n = 282) and telomere length (n = 246) was significant (P < .001, respectively). Telomere length was a prognostic factor for stage A (P = .021) and stage B/C (P = .018) patients, whereas mutation status predicted outcome only in stage A patients (P < .001). Furthermore, mutated CLLs were subdivided by telomere length into 2 groups with different prognoses (P = .003), a subdivision not seen for unmutated cases (P = .232). Interestingly, the V<sub>H</sub>-mutated group with short telomeres had an overall survival close to that of the unmutated cases. Thus, by combining V<sub>H</sub> mutation status and telomere length, an improved subclassification of CLL was achieved identifying previously unrecognized patient groups with different outcomes. (Blood. 2005;105:4807-4812)

© 2005 by The American Society of Hematology

## Introduction

The end structures of the chromosomes, the telomeres, are composed of a repetitive DNA sequence, (TTAGGG)<sub>n</sub>, and specific proteins bound to the DNA.<sup>1,2</sup> The telomeres protect the chromosomes from degradation, prevent end-to-end fusions, and are crucial for control of replicative senescence. In humans, the telomeres have an average length of 5 kilobases (kb) to 15 kb and in normal somatic cells the telomeric DNA shortens with 100 base pair (bp) to 200 bp every cell division due to the end-replication problem.3-5 The erosion of the telomeres can be counteracted by telomerase, an enzyme that adds TTAGGG repeats to the chromosomal ends.6 Telomere maintenance, usually executed by telomerase, is a prerequisite for an extended or infinite cellular lifespan, and studies of telomere dynamics have been in focus ever since it was shown that telomerase activity is present in almost 90% of all malignant tumors.7-9 The nearly exclusive presence of telomerase in tumor cells has made the enzyme a theoretically attractive target for cancer therapy. In contrast, telomerase is restricted to a few normal cell types in humans, including germ cells, stem cells, activated lymphocytes, and epithelial cells with high reproductive demand.<sup>10-14</sup> Additionally, during the germinal center (GC) reaction in lymph nodes a high level of telomerase activity is expressed in the GC B cells accompanied by a unique telomere lengthening process not observed in other cells in vivo.<sup>15-17</sup>

Telomere length reduction has been found with increasing age and was recently implicated as a predictive factor for overall survival, as high overall mortality was associated with short

From the Department of Medical Biosciences, Pathology, Umeå University, Umeå; Department of Medicine, Linköping University, Linköping; and Departments of Genetics and Pathology, Medical Sciences and Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden.

BLOOD, 15 JUNE 2005 • VOLUME 105, NUMBER 12

telomeres in peripheral blood cells in healthy individuals.<sup>18</sup> Tumor cells often have shorter telomeres than cells from age-matched controls. Still, only a few studies have found a link between telomere length in malignant cells and prognosis. In myelodysplastic syndromes, short telomeres correlated with increased risk for transformation to acute leukemia and in chronic myeloid leukemia with a worse prognosis.<sup>19-22</sup> In myeloma, a subgroup of cases with high telomerase activity and short telomeres had an increased mortality rate.<sup>23</sup>

B-cell chronic lymphocytic leukemia (CLL) is characterized by a monoclonal expansion of small B lymphocytes previously supposed to be derived from naive B cells of the mantle zone.<sup>24</sup> However, analyses of the immunoglobulin heavy-chain variable region (IgV<sub>H</sub>) gene have shown that CLL can be divided into 2 subsets comprising cases with somatically mutated and unmutated V<sub>H</sub> genes.<sup>25-28</sup> A more favorable prognosis has been found for CLL cases with mutated V<sub>H</sub> genes compared with unmutated cases.<sup>29-32</sup> Somatic hypermutation of Ig genes is a normal process occurring in the GC reaction as part of the antigen-driven affinity maturation of antibodies.<sup>33</sup> CLL cases with germ line V<sub>H</sub> genes are hence considered to originate from pre-GC B lymphocytes and the mutated from GC-experienced B lymphocytes. Interestingly, in a recent study a strong correlation existed between V<sub>H</sub> gene mutation status and telomere length, where mutated (post-GC) CLL cases

Uppsala University, and by grant QLG1-1999-01341 from the European Union (G.R.).

Reprints: Göran Roos, Department of Medical Biosciences, Pathology, Umeå University, SE-90187 Umeå, Sweden; e-mail: goran.roos@medbio.umu.se.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2005 by The American Society of Hematology

Submitted November 17, 2004; accepted January 19, 2005. Prepublished online as *Blood* First Edition Paper, March 3, 2005; DOI 10.1182/blood-2004-11-4394.

Supported by grants from the Swedish Cancer Society, the Medical Faculty, Umeå University, Lion's Cancer Research Foundation at Umeå University and

had longer telomeres than germ line (pre-GC) cases.<sup>32</sup> A similar pattern was also described in some cases of familial CLL after age adjustment of telomere lengths.<sup>34</sup> The telomere length and mutation status in CLL thus appear to be linked, possibly reflecting the origin of the clonal cells with regard to the GC reaction. Furthermore, both telomere length and telomerase activity have been found to be associated with outcome in CLL, since a shorter survival was associated with short telomeres and high telomerase activity.<sup>32,35,36</sup> However, in a recent study telomere length analyzed by flowfluorescence in situ hybridization (FISH) was not a significant prognostic factor for CLL.<sup>37</sup>

In the present study, a large series of CLL cases have been analyzed for telomere length, using a recently described polymerase chain reaction (PCR) method<sup>38</sup> and in a subset also by flow-FISH.<sup>39,40</sup> The telomere data were analyzed in relation to V<sub>H</sub> gene mutation status, stage, and overall survival. The correlations between V<sub>H</sub> gene mutation status, telomere length, and prognosis previously shown were verified. Furthermore, we could show that telomere length could further subdivide the V<sub>H</sub>-mutated cases into 2 groups with significantly different outcomes, where the group with short telomeres had a prognosis similar to V<sub>H</sub> gene–unmutated cases. Thus, by combining Ig gene mutation analysis and telomere length evaluation, a better subclassification of CLL can be achieved.

# Patients, materials, and methods

#### Patients

Tumor samples from 310 patients with CLL diagnosed between 1973 and 2002 were obtained from the archives of the Departments of Pathology at the University Hospitals in Umeå (n = 74), Uppsala (n = 156), and Linköping (n = 80), Sweden. The tumor material was acquired from peripheral blood (178 cases, 58%), bone marrow (91 cases, 29%), lymph node (32 cases, 10%), and spleen (9 cases, 3%). There were 216 male (70%) and 94 female (30%) patients with a male-female ratio of 2.3:1. Survival data were available for 296 patients from Swedish population and cancer registries. The median age at diagnosis was 66 years (range, 32-88 years) and the median survival time (estimated by Kaplan-Meier method) was 85 months. Patient follow-up extended from 1 month to 189 months with a median value of 61 months. Data on staging according to Binet were available for 201 patients (110 stage A and 91 stage B or C). Informed consent was provided according to the Declaration of Helsinki, and the study was approved by the ethics committee of Uppsala University (Ups 01-082).

#### Morphology and immunophenotyping

Besides morphologic classification of smears, sections, and imprints, immunophenotyping was performed on all samples using flow cytometry and a panel of monoclonal antibodies. Only cases fulfilling the criteria for CLL (CD5<sup>+</sup>, CD19<sup>+</sup>, CD23<sup>+</sup>, and a weak expression of surface Ig) in the Royal Marsden scoring system were included.<sup>24</sup>

# Telomere length measurement by quantitative real-time PCR (Tel-PCR)

The method for relative telomere length measurement using real-time PCR has been described<sup>38</sup> and is here called Tel-PCR. Briefly, genomic DNA samples diluted to approximately 1.75 ng/ $\mu$ L were incubated for 5 minutes at 95°C, cooled on ice for 5 minutes, and centrifuged briefly at 730g. Two separate PCR runs were performed for each sample, the first to determine the cycle threshold (Ct) value for telomere amplification (plate 1), and the second to determine the Ct value for control gene amplification (plate 2). A standard curve was generated in each run, consisting of reference DNA (CCRF-CEM cell line) diluted serially. Both reference and sample DNA were analyzed in triplicate (35 ng DNA/aliquot).

Two master mixes of PCR reagents were prepared, one for telomere amplification and one for control gene ( $\beta$ 2-globin on chromosome 11)

amplification. The final concentrations of the PCR reagents were 1.25 U AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA), 150 nM 6-ROX and 0.2x Sybr Green I (Roche Diagnostics GmBH, Mannheim, Germany), 50 mM KCl, 2 mM MgCl<sub>2</sub>, 0.2 mM of each deoxynucleoside triphosphate (dNTP) (MBI Fermentas, Amherst, NY), 5 mM dithiothreitol (DTT), 1% dimethyl sulfoxide (DMSO), and 15 mM Tris-HCl pH 8.0. The final telomere primer concentrations were: tel 1, 270 nM; tel 2, 900 nM. In the control gene master mix primers HBG1 and HBG2 were used at the concentration of 400 nM. The primer sequences (written  $5'\ddagger3'$ ) were as follows: tel 1, GGTTTTTGAGGGTGAGGGTGAGGGT; tel 2, TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCTATCCCACC.

Telomere sequences were amplified in a Prism 7000 sequence Detection System (Applied Biosystems) using the following conditions: 95°C, 10 minutes, to activate Taq polymerase; 35 cycles of denaturation at 95°C, 15 seconds, and annealing/extension at 54°C, 2 minutes. The conditions for HBG gene amplification were: 95°C, 10 minutes; 40 cycles at 95°C, 15 seconds, and 58°C, 1 minute. ABI Prism 7000 SDS Software v 1.0 was used for analysis.

The Ct values generated in both runs were used to calculate relative telomere–single-copy-gene ratio (T/S) values for each sample:  $T/S = 2^{-\Delta Ct}$  (where  $\Delta Ct = Ct_{control}-Ct_{telomere}$ ).

#### Telomere length estimated by Southern blotting

In order to verify the reliability of the Tel-PCR method, 43 CLL samples included in this study were also analyzed for telomere length by Southern blotting. Hybridization with a telomeric probe (TTAGGG)<sub>4</sub> was performed and mean telomere restriction fragment (TRF) length was calculated as described.<sup>41</sup> The lambda DNA/EcoI StyI/MluI Marker (MBI Fermentas) and the DNA molecular weight marker X (Boehringer Mannheim Gmbh, Mannheim, Germany) were used as molecular weight standards.

# Fluorescence in situ hybridization and flow cytometry (flow-FISH)

A subset of the CLL cases (n = 87) was analyzed using a previously described flow cytometric assay for telomere length estimation.<sup>39</sup> All samples tested had been DMSO frozen at the time of sampling and kept in liquid nitrogen until analysis. After in situ hybridization with a fluorescein-labeled PNA probe,  $(C_3TA_2)_3$ , and DNA staining with propidium iodide the samples were run in a flow cytometer (FACS Calibur; Becton Dickinson, San Jose, CA). The tetraploid T-cell line 1301 with very long telomeres was used as an internal control. Telomere length was given as an arbitrary value derived from the ratio between the signal intensity of the internal control and the sample and where the 1301 signal was set to 1. Compensation for cellular DNA content was made as described.<sup>39</sup>

#### V<sub>H</sub> gene analysis

 $V_H$  gene family-specific PCR amplification was performed on genomic DNA using 6 family-specific  $V_H$  primers and one  $J_H$  as previously described.<sup>42</sup> Clonal PCR products were sequenced directly or using cloning of the PCR products as previously outlined.<sup>42,43</sup> All sequence reactions were analyzed using an automated DNA sequencer (ABI 377 or ABI3700, Applied Biosystems; and MegaBACE 500 DNA Analysis System, Amersham Biosciences, Piscataway, NJ). The sequences were aligned to IgH sequences from the GenBank database (National Center for Biotechnology Information, Bethesda, MD), the V-BASE database (MRC, Centre for Protein Engineering, Cambridge, United Kingdom), and the Immunogenetics database (http://imgt.cines.fr:8104). A  $V_H$  gene sequence deviating more than 2% from the corresponding germ line gene was defined as mutated.<sup>44</sup>

#### Statistical analyses

Kaplan-Meier survival curves and the log-rank test were performed to study the prognostic significance of  $V_H$  gene mutation status and telomere length in CLL using SPSS (SPSS, Chicago, IL.) Survival was calculated from the date of diagnosis until the last follow-up or death. Nonparametric correlation was calculated according to Spearman rank correlation. Differences



Figure 1. Correlation between telomere length estimated by Southern blotting and Tel-PCR. A significant correlation was found ( $r^2 = 0.818$ , P < .001), giving the mathematical relation: Y = 3.1989X + 3.1280. TRF indicates telomere restriction fragment.

between groups were analyzed with Pearson Chi-square. Probabilities of less than .05 were accepted as a significant value. Cox multiple regression was used to analyze the independence of the potential prognostic parameters of age, stage according to Binet, mutation status (cut off at 98% homology), and telomere length (cut off at median T/S value).

## Results

#### **Telomere length determination**

In 246 of the 310 CLL cases, DNA was available for telomere length analysis by the PCR method. For 43 cases telomere length data were also assessed by Southern blotting, showing a high correlation to the Tel-PCR results (P < .001,  $r^2 = 0.818$ ; Figure 1). The Tel-PCR technique provides a relative T/S value for each sample in our CLL cases with a range from 0.01 to 2.21 with a mean value of 0.373. T/S values can be converted to TRF (telomere restriction fragment) length values in kb using the data shown in Figure 1 and in the present CLL material the "transformed" T/S values varied from 3.16 to 9.97 kb. The TRF value at a Tel-PCR value equal to 0 gives an estimation of the average subtelomeric DNA included in the Southern blot evaluation. The value obtained in our material using Tel-PCR ( $\sim 3.1$  kb, Figure 1) corresponds very well to previous estimations using Southern blotting after *Bal*31 digestions or using flow-FISH.<sup>4,39</sup>

The time from diagnosis to sampling varied in our CLL cohort. In the group analyzed by Tel-PCR, 148 cases were sampled within one year and 78 cases after more than a year (mean 50 months) after diagnosis. Since telomeres are lost by time, we studied if the time span between diagnosis and sample collection could be of importance. No statistical difference in telomere lengths was found when comparing different time spans from diagnosis to sample collection (0-1, 1-3, and > 3 years; P = .530), indicating that this time factor did not influence the further analysis. A subset of 87 CLL cases was also studied for telomere length using the flow-FISH approach. For these cases, PCR telomere length data, but not Southern blot results, were available. A statistically significant association was found between the Tel-PCR and flow-FISH data (P = .001,  $r^2 = 0.145$ ) (not shown).

#### Analysis of V<sub>H</sub> gene mutations

Ig gene mutation data were successfully achieved from 297 patients. A total of 172 cases demonstrated unmutated  $V_H$  genes (> 98% homology to germ line) and 126 cases showed somatic  $V_H$  gene mutations (< 98% homology). Among the mutated samples 68 cases displayed less than 95% and 58 cases 95% to 98% homology. In 13 samples no mutation status data could be obtained. Two clonal rearrangements were found in 48 cases, 10 of which showed 2 mutated  $V_H$  genes (regarded as mutated), 28 with 2 unmutated genes (regarded as unmutated), and 8 with one mutated and one unmutated  $V_H$  gene (regarded as mutated). One case had 3 mutated  $V_H$  genes and one case with one mutated and 2 unmutated genes was considered as mutated.

#### Telomere length in relation to V<sub>H</sub> gene mutation status

A significant correlation was found for the CLL cases comparing telomere length estimation by Tel-PCR and V<sub>H</sub> gene mutation status, with longer telomeres in mutated cases (P < .001). The mean Tel-PCR value for mutated cases was 0.51 and for unmutated 0.26. In the  $V_H$  gene-mutated group cases with less than 95% homology to germ line had significantly longer telomeres (mean T/S = 0.63) compared with cases with 95% to 98% homology (mean T/S = 0.39; P < .01). Furthermore, sample site seemed to be of relevance for this association. In blood and bone marrow samples a significant correlation existed between telomere length and  $V_{\rm H}$  gene mutation status (P < .001), but not in samples from lymph nodes (P = .119) (not shown). No significant difference existed in number of mutated and unmutated cases depending on sample site (P = .676, Table 1). However, when the mutated cases were divided into 2 groups (< 95% and 95%-98% homology, respectively), significantly more lymph node cases were found in the group with higher sequence homology than in blood and bone marrow samples (Pearson Chi-square P = .002; Table 2). No significant differences in telomere length, sex, or age distribution were observed with regard to sample site (data not shown).

#### Survival analysis

When the patient material was divided into mutated (n = 121) and unmutated (n = 162) cases, a statistically significant difference in overall survival was found between the groups (P < .001) (Figure 2A). The median survival for patients with mutated V<sub>H</sub> genes was 120 months and for those without mutations it was 68 months, calculated from the date of diagnosis. Regarding telomere length, analysis was performed dividing the material at the median Tel-PCR value showing a highly significant difference in survival (P < .001, Figure 2B). The median survival for cases with longer telomeres (Tel-PCR T/S value > 0.3) was 121 months compared with 78 months in the group with lower telomere signal (Tel-PCR T/S value < 0.3).

When analyzing  $V_H$  gene mutation status and telomere length for survival in relation to sample type, a significant correlation to survival was found in bone marrow/blood samples for both mutation status and telomere length (P < .001, respectively; Figure 3A-B). However, no difference in survival existed among the

Table 1.  $V_H$  gene mutation status in CLL samples according to sample site

	Bone marrow, no. cases	Blood, no. cases	Lymph node, no. cases	Spleen, no. cases	Total, no. cases
Unmutated cases	45	103	17	7	172
Mutated cases	41	68	14	2	125
All cases	86	171	31	9	297

Table El Blethbatten el elle caceo man matatea (A geneci, by cample che ana coquence nemerogy	Table 2.	Distribution	of CLL cases	s with mutated \	/ <sub>H</sub> genes, b	y sample site and	sequence	homology
-----------------------------------------------------------------------------------------------	----------	--------------	--------------	------------------	-------------------------	-------------------	----------	----------

	Bone marrow, no. cases	Blood, no. cases	Lymph node, no. cases	Spleen, no. cases	Total, no. cases
Sequence homology 95%-98%	19	24	12	2	57
Sequence homology less than 95%	22	44	2	0	68
All cases	41	68	14	2	125

CLL cases with mutated V<sub>H</sub> genes were divided at 95% sequence homology (the median frequency of homology to germline for the mutated cases) with regard to sample site. The data show a significant difference between groups (P = .002, Pearson Chi-square). Lymph node/spleen samples demonstrated a lower mutation frequency than bone marrow/blood samples.

lymph node samples (Figure 4A-B). For stage A patients the mutation status was a significant prognostic factor (P < .001) as was the Tel-PCR data (P = .0206; Figure 5A-B). Mutation status could not predict outcome for stage B/C patients (P = .1225; Figure 6A), in contrast to telomere length (P = .0177; Figure 6B).

Furthermore, the prognostic value of telomere length was significant for V<sub>H</sub> gene–mutated cases but not for unmutated cases (P = .0031 and .2324, respectively). V<sub>H</sub>-mutated cases with short telomeres had a slightly better prognosis than unmutated cases (mean survival time 87 and 73 months, respectively; not significant) but significantly worse than a group with favorable outcome (mean survival time 127 months) defined as V<sub>H</sub> gene mutation homology less than 98% and telomere length more than median (Figure 7; P = .001).

CLL cases with a clonal rearrangement involving the V<sub>H</sub>3-21 gene are usually mutated but constitute a subgroup of CLL with an outcome comparable to unmutated cases.<sup>45</sup> In the present material, V<sub>H</sub>3-21 cases were characterized by short telomeres (mean T/S value = 0.33) compared with mutated cases (mean T/S = 0.51), and analysis after excluding the V<sub>H</sub>3-21 cases still showed a significant difference in survival in the V<sub>H</sub>-mutated cases subgrouped after telomere length (P < .001).

Since CLLs with lymph node– and spleen-derived samples differed from the other CLLs with respect to several characteristics, they were excluded from the multiple regression analysis. Thus, in our CLL cases with bone marrow and peripheral blood samples the close association between mutation status and telomere length was demonstrated in the multivariate analysis with mutation status as the strongest prognostic indicator. When mutation status was excluded from the multivariate analysis telomere length (P = .003), Binet stage (P = .005), and age (P = .026), but not sex (P = .794) were independent prognostic factors. If only IgV<sub>H</sub>-mutated cases were analyzed, Binet stage was a significant prognostic factor (P = .005) but telomere length (P = .439) was not, indicating an association between short telomeres and higher stage and/or long telomeres and lower stage for this subgroup.

A subset of patients (n = 87) was also analyzed by flow-FISH but with this technique no difference in survival (P = .426) was achieved using a cut-off at the median flow-FISH value of  $0.106^{39}$  (corresponding to about 5.5 kb in Southern blot TRF analysis) (not shown).

### Discussion

Using Ig gene analysis, CLL can be divided into at least 2 groups, consisting of cases with somatically mutated or unmutated  $V_H$  genes with a significantly better prognosis for the mutated, GC-experienced cases.<sup>25-32</sup> In the present study, this subdivision according to  $V_H$  gene mutation status was again confirmed. Furthermore, the clinical value of telomere length assessment in CLL was demonstrated using a recently described quantitative PCR method<sup>38</sup> in our large cohort of CLL cases. Of special interest is that a combination of telomere length and  $V_H$  gene mutation status could identify 2 previously unrecognized patient groups among the  $V_H$ -mutated cases, one with longer telomeres and a favorable outcome and one with shorter telomeres and an unfavorable outcome.

During the GC reaction, telomerase is strongly up-regulated in the activated GC B cells, subsequently followed by a notable telomere elongation.<sup>15-17</sup> This appears to be reflected in mature B-cell disorders in which GC-derived tumors have been found to exhibit longer telomeres than GC-inexperienced neoplasms.<sup>46</sup> Thus, GC-derived follicular lymphomas, Burkitt lymphomas, and diffuse large B-cell lymphomas demonstrated longer telomeres than CLL and mantle cell lymphomas.<sup>46</sup> For CLL the telomere length is strongly associated with mutation status<sup>32,37,46</sup> and cases with long telomeres have a significantly better outcome compared with cases with shorter telomeres.<sup>32,35</sup> These observations were further verified in the present study on a large cohort of CLL cases. Thus, GC-experienced CLL cells are characterized by hypermutated IgV<sub>H</sub> genes and longer telomeres.

The biologic background to the connection between telomere length and outcome can only be speculated upon. Since there is a very strong association between  $V_H$  gene mutation status and telomere length in normal as well as in malignant samples,<sup>15-17,32,46</sup> it can be argued that telomere length is merely a "pseudo marker" for GC-experienced B cells. However, further analysis of the relationship between telomere length and  $V_H$  gene mutation status demonstrated that 2 patient subgroups with a significantly different outcome could be identified among the  $V_H$  gene–mutated cases. These patient groups have previously been unrecognized and are



Figure 2. Survival analysis in relation to  $V_H$  gene mutation status and telomere length determined by Tel-PCR. (A)  $V_H$  gene mutation status; (B) telomere length by Tel-PCR.



Figure 3. Survival analysis in bone marrow/blood samples. Figure shows survival in relation to  $V_H$  gene mutation status (A) and telomere length determined by Tel-PCR (B).



Figure 4. Survival analysis in lymph node samples. Figure shows survival in relation to  $V_H$  gene mutation status (A) and telomere length determined by Tel-PCR (B).

important to identify, especially since the outcome for cases with mutated V<sub>H</sub> genes and short telomeres did not differ significantly from the unmutated group. Previously it has been demonstrated that extensive telomere shortening promotes genetic instability (reviewed in Hacket and Greider<sup>47</sup>) and that CLL unmutated cases show more genetic aberrations than the V<sub>H</sub> gene-mutated cases.<sup>48</sup> These data indicate that in CLL, short telomeres can be a significant contributing factor to genetic instability and thereby also be an important prognostic parameter. An interesting future task will be to characterize V<sub>H</sub>-mutated CLL cases regarding genetic alterations in relation to telomere status. For clinical stage there seemed to be a difference between mutation status and telomere length regarding prognostication strength, since both parameters were highly significant for stage A patients, whereas only telomere length showed this power for stage B/C patients. In a recent French study, mutational status and stage were independent and complementary prognostic indicators in CLL,49 indicating to us unknown differences between the 2 patient groups. In IgV<sub>H</sub>-mutated CLL there seemed to be an association between stage and telomere length, suggesting that for this subgroup shorter telomeres and higher stage indicated a worse prognosis. This further substantiates the need to characterize, in detail, mutated CLL regarding genetic features at the chromosomal and molecular level.

In the nodal samples neither mutation status nor telomere length seemed to be a factor of prognostic relevance. It cannot be ruled out that CLL preferentially affecting lymphoid tissue could differ in some respects from the "common" CLL in blood and bone marrow, rendering mutation status or telomere length less important for the outcome. However, the nodal cases were few in the present study and a larger study cohort is needed to verify the difference indicated.

In CLL a biased usage of the V<sub>H</sub>3-21 and V<sub>H</sub>1-69 genes has been reported.<sup>45,50,51</sup> V<sub>H</sub>1-69 cases are preferentially unmutated whereas V<sub>H</sub>3-21 cases often are mutated. However, irrespective of the mutation status the V<sub>H</sub>3-21 cases showed a similar clinical course to unmutated cases.<sup>45,51</sup> Therefore, a connection between V<sub>H</sub>3-21 usage and mutated cases with short telomeres could be



Figure 5. Survival analysis in stage A patients. Figure shows survival in relation to  $V_H$  gene mutation status (A) and telomere length determined by Tel-PCR (B).



Figure 6. Survival analysis in stage B/C patients. Figure shows survival in relation to  $V_H$  gene mutation status (A) and telomere length determined by Tel-PCR (B).

suspected, which was confirmed in this study. Accordingly, after excluding the  $V_{\rm H}$ 3-21 cases from the analysis, mutated cases still could be subdivided into 2 groups with different outcomes, depending on the telomere length.

The application of the Tel-PCR methodology for telomere length analysis was shown to be highly consistent with Southern blot results, confirming its usefulness for telomere measurements. Compared with Southern blotting, the PCR approach is more convenient, since it is rapid and requires considerably less DNA. One possibly important feature of the PCR method is that only telomere repeats are amplified and recorded, excluding the subtelomeric parts included in the Southern blots. In the PCR method the telomere value has to be related to the value obtained for a single copy gene and for this purpose we have used the  $\beta$ -globin gene on chromosome 11. An alternative in the literature is 36B4 on chromosome 12,38 but since trisomy 12 is common in CLL we wanted to exclude the possibility of a bias due to a DNA imbalance. We did, however, compare the effect of trisomy 12 using both single-copy genes as loading controls in a few cases with known trisomy 12 and no obvious difference was shown, indicating that a disomy versus trisomy DNA difference is of minor importance after completion of the amplification rounds (P.G., unpublished data, January 2005).

In a recent study,<sup>37</sup> no significant prognostic relevance of telomere length in CLL was found using flow-FISH. These data are in accordance with our present results using flow-FISH on a subset of the CLL samples. Our impression is that the flow technique is less reliable in the analysis of samples kept frozen in DMSO for many years. The correlation between our flow-FISH data and Southern blotting or Tel-PCR is indeed better using fresh cells compared with DMSO frozen samples (M.H., unpublished data,



Figure 7. Survival analysis in CLL after subdivision according to mutation status and telomere length determined by Tel-PCR as indicated in the figure.

April 2004). Thus, for telomere length analysis of stored material, Tel-PCR seems to be the method of choice.

In conclusion, telomere length is a clinically significant factor in CLL and in combination with Ig gene–mutation analysis a better subclassification of CLL can be achieved, identifying 2 previously unrecognized patient groups with different outcomes.

# References

- Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence, (TTAGGG), present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A. 1988; 85:6622-6626.
- 2. Blasco MA. Telomerase beyond telomeres. Nat Rev Cancer. 2002;2:627-633.
- Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345:458-460.
- de Lange T, Shiue L, Myers RM, et al. Structure and variability of human chromosome ends. Mol Cell Biol. 1990;10:518-527.
- Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication problem and cell aging. J Mol Biol. 1992;225:951-960.
- Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989;59:521-529.
- Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33: 787-791.
- Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349-352.
- Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol. 1998;8:279-282.
- Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266:2011-2015.
- Hiyama K, Hirai Y, Kyoizumi S, et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol. 1994;155: 3711-3715.
- Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996;18:173-179.
- Härle-Bachor C, Boukamp P. Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci U S A. 1996;93:6476-6481.
- Norrback K-F, Dahlenborg K, Carlsson R, Roos G. Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood. 1996;88:222-229.
- Hu BT, Lee SC, Marin E, Ryan DH, Insel RA. Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. J Immunol. 1997;159:1068-1071.
- Weng N-P, Granger L, Hodes RJ. Telomere lengthening and telomerase activation during human B cell differentiation. Proc Natl Acad Sci U S A. 1997;94:10827-10832.
- Norrback K-F, Hultdin M, Dahlenborg K, Osterman P, Carlsson R, Roos G. Telomerase regulation and telomere dynamics in human germinal centers. Eur J Haematol. 2001;67:309-317.
- Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361:393-395.
- 19. Ohyashiki JH, Ohyashiki K, Fujimura T, et al. Telomere shortening associated with disease

evolution patterns in myelodysplastic syndromes. Cancer Res. 1994;54:3557-3560.

- Ohyashiki JH, Iwama H, Yahata N, et al. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clin Cancer Res. 1999;5:1155-1160.
- Boultwood J, Peniket A, Watkins F, et al. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood. 2000;96:358-361.
- Brummendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood. 2000;95:1883-1890.
- Wu KD, Orme LM, Shaughnessy J, Jacobson J, Barlogie B, Moore MA. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status and overall survival. Blood. 2003;101:4982-4989.
- Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640-1645.
- Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525.
- Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
- Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
- Maloum K, Davi F, Merle-Beral H, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood. 2000;96:377-379.
- Thunberg U, Johnson A, Roos G, et al. CD38 expression is a poor predictor for V<sub>H</sub> gene mutational status in chronic lymphocytic leukemia. Blood. 2001;97:1892-1893.
- Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177-1184.
- Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.
- Hultdin M, Rosenquist R, Thunberg U, et al. Association between telomere length and V<sub>H</sub> gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer. 2003;88:593-598.
- MacLennan IC. Germinal centers. Annu Rev Immunol. 1994;12:117-139.
- Ishibe N, Prieto D, Hosack DA, et al. Telomere length and heavy-chain mutation status in familial chronic lymphocytic leukemia. Leuk Res. 2002; 26:791-794.
- Bechter OE, Eisterer W, Pall G, Hilbe W, Kühr T, Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4918-4922.

# Acknowledgments

The authors are grateful to Elisabeth Grönlund, Eleonor Lindström-Eriksson, and Kent Persson for skillful technical assistance. Richard Palmqvist is appreciated for statistical help.

- Tchirkov A, Chaleteix C, Magnac C, et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol. 2004;15:1476-1480.
- Damle RN, Battiwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobin V gene mutations. Blood. 2004;103:375-382.
- Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30:e47.
- Hultdin M, Grönlund E, Eriksson-Lindström E, Norrback K-F, Just T, Roos G. Telomere analysis by fluorescence in situ hybridization and flow cytometry. Nucleic Acids Res. 1998;26:3651-3656.
- Rufer N, Dragowska W, Dumont-Girard F, Chapuis B, Roosnek E, Lansdorp PM. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol. 1998;16:743-747.
- Mehle C, Ljungberg B, Roos G. Telomere shortening in renal cell carcinoma. Cancer Res. 1994; 54:236-241.
- Li AH, Rosenquist R, Forestier E, et al. Clonal rearrangements in childhood and adult precursor B acute lymphoblastic leukemia: a comparative polymerase chain reaction study using multiple sets of primers. Eur J Haematol. 1999;63:211-218.
- Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood. 2004;104:2879-2885.
- Matsuda F, Shin EK, Nagaoka H, et al. Structure and physical map of 64 variable segments in the 3'0.8- megabase region of the human immunoglobulin heavy-chain locus. Nat Genet. 1993;3: 88-94.
- Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99:2262-2264.
- Ladetto M, Compagno M, Ricca I, et al. Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. Blood. 2004;103:4644-4649.
- Hacket JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene. 2002;21:619-626.
- Karhu R, Tobin G, Thunberg U, et al. More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2003;37:417-420.
- Vasconcelos Y, Davi F, Levy V, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol. 2003;21: 3928-3932.
- Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol. 1997;158:235-246.
- Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3–21 gene display highly restricted Vlambda2–14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003;101: 4952-4957.